These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 31367864)
21. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350 [TBL] [Abstract][Full Text] [Related]
22. Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-κB pathway. Tey SK; Tse EYT; Mao X; Ko FCF; Wong AST; Lo RC; Ng IO; Yam JWP Cancer Lett; 2017 Dec; 411():150-161. PubMed ID: 28989054 [TBL] [Abstract][Full Text] [Related]
23. Telmisartan-Induced Cytotoxicity via G Tsujiya Y; Hasegawa A; Yamamori M; Okamura N Biol Pharm Bull; 2021; 44(12):1878-1885. PubMed ID: 34853271 [TBL] [Abstract][Full Text] [Related]
24. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression. Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054 [TBL] [Abstract][Full Text] [Related]
26. Albendazole-loaded cubosomes interrupt the ERK1/2-HIF-1α-p300/CREB axis in mice intoxicated with diethylnitrosamine: A new paradigm in drug repurposing for the inhibition of hepatocellular carcinoma progression. Saber S; Nasr M; Saad AS; Mourad AAE; Gobba NA; Shata A; Hafez AM; Elsergany RN; Elagamy HI; El-Ahwany E; Amin NA; Girgis S; Elewa YHA; Mahmoud MH; Batiha GE; El-Rous MA; Kamal I; Kaddah MMY; Khodir AE Biomed Pharmacother; 2021 Oct; 142():112029. PubMed ID: 34416629 [TBL] [Abstract][Full Text] [Related]
27. Activation of peroxisome proliferator-activated receptor-gamma inhibits tumor growth by negatively regulating nuclear factor-κB activation in patients with hepatocellular carcinoma. Nojima H; Kuboki S; Shinoda K; Shimizu H; Ohtsuka M; Kato A; Yoshitomi H; Furukawa K; Takayashiki T; Miyazaki M J Hepatobiliary Pancreat Sci; 2016 Sep; 23(9):574-84. PubMed ID: 27451128 [TBL] [Abstract][Full Text] [Related]
28. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046 [TBL] [Abstract][Full Text] [Related]
29. Role of transforming growth factor-activated kinase-1 on tumor necrosis factor-α actions in human adipose tissue-derived stromal cells. Lee SY; Lee JH; Shin KK; Kim DS; Kim YS; Bae YC; Jung JS Stem Cells Dev; 2015 Apr; 24(7):836-45. PubMed ID: 25350220 [TBL] [Abstract][Full Text] [Related]
31. Cyclovirobuxine D Exerts Anticancer Effects by Suppressing the Zhang J; Chen Y; Lin J; Jia R; An T; Dong T; Zhang Y; Yang X DNA Cell Biol; 2020 Mar; 39(3):355-367. PubMed ID: 31913706 [TBL] [Abstract][Full Text] [Related]
32. MicroRNA-6809-5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1. Yang PW; Lu ZY; Pan Q; Chen TT; Feng XJ; Wang SM; Pan YC; Zhu MH; Zhang SH Phytomedicine; 2019 Apr; 57():18-29. PubMed ID: 30668319 [TBL] [Abstract][Full Text] [Related]
33. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. Yang C; Qin S Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780 [TBL] [Abstract][Full Text] [Related]
34. Phosphorylation of PPARγ at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4. Shu Y; Lu Y; Pang X; Zheng W; Huang Y; Li J; Ji J; Zhang C; Shen P Oncotarget; 2016 Nov; 7(47):76984-76994. PubMed ID: 27769068 [TBL] [Abstract][Full Text] [Related]
36. RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma. Zhang M; Li Q; Zhang L; Wang Y; Wang L; Li Q; He T; Wan B; Wang X Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):73-79. PubMed ID: 29729697 [TBL] [Abstract][Full Text] [Related]
38. Identification of a new TRAF6 inhibitor for the treatment of hepatocellular carcinoma. Li N; Luo L; Wei J; Liu Y; Haque N; Huang H; Qi Y; Huang Z Int J Biol Macromol; 2021 Jul; 182():910-920. PubMed ID: 33865893 [TBL] [Abstract][Full Text] [Related]
39. TIPE2 inhibits TNF-α-induced hepatocellular carcinoma cell metastasis via Erk1/2 downregulation and NF-κB activation. Zhang YH; Yan HQ; Wang F; Wang YY; Jiang YN; Wang YN; Gao FG Int J Oncol; 2015 Jan; 46(1):254-64. PubMed ID: 25339267 [TBL] [Abstract][Full Text] [Related]
40. Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma. Vara D; Morell C; Rodríguez-Henche N; Diaz-Laviada I Cell Death Dis; 2013 May; 4(5):e618. PubMed ID: 23640460 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]